Design
Review
Authors
Loading...
Atrial-selective K+ channel drugs may improve AF treatment safety; leaves open clinical translation of these novel agents.
Key points are not available for this paper at this time.
Ursula Ravens (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: